Search

Background: Postoperative mortality for oropharynx squamous cell carcinoma (OPSCC) with transoral robotic surgery (TORS) varies from 0.2% to 6.5% on trials; the real‐world rate is unknown. Methods: NCDB study from 2010 to 2017 for patients with cT1‐2N0‐2M0 OPSCC with Charleson–Deyo score 0–1. Ninety‐day mortality assessed from start and end of treatment at Commission on Cancer‐accredited facilities. Results: 3639 patients were treated with TORS and 1937 with radiotherapy. TORS cohort had more women and higher income, was younger, more often treated at academic centers, and more likely to have private insurance (all p < 0.05). Ninety‐day mortality was 1.3% with TORS and 0.7% or 1.4% from start or end of radiotherapy, respectively. From end of therapy, there was no significant difference on MVA between treatment modality. Conclusions: There is minimal difference between 90‐day mortality in patients treated with TORS or radiotherapy for early‐stage OPSCC. While overall rates are low, for patients with expectation of cure, work is needed to identify optimal treatment. [ABSTRACT FROM AUTHOR]

Introduction: To report on SBRT as a bridge to OLT for patients with HCC and Child-Pugh =8 cirrhosis. Methods: Retrospective review of 15 patients, treated from 2010-2017. Three patients excluded secondary to delisting from prohibitive substance. Twelve patients (17 lesions) included for final analysis. Hepatic SPECT functional treatment planning utilized. Results: The median age of 60 years with a median CP 9 and MELD 14. The median SBRT dose was 40 Gy in 5 fractions, and median tumor size was 2.3cm (1.2-5.3cm). Median follow-up and survival was 40-months and 46-months, respectively. One patient succumbed to renal/hepatic failure before OLT. Radiographic response was 80%. pCR at explant was 46%. No grade = 3 acute toxicities. Median time to progression of CP = 2 was 9.7-months and MELD progression was not met before OLT. Conclusion: SBRT with functional treatment planning can be used safely as a bridge to OLT in select patients with CP =8 cirrhosis. [ABSTRACT FROM AUTHOR]